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Recommendation for use of the newly introduced 
pneumococcal protein conjugate vaccines in Korea
Streptococcus pneumoniae remains a leading cause of invasive 
infections including bacteremia and meningitis, as well as mucosal 
infections such as otitis media and pneumonia among children 
and adults. The 7-valent pneumococcal conjugate vaccine (PCV7) 
was licensed for use among infants and young children in many 
countries including Korea. The routine use of PCV7 has resulted in 
a decreased incidence of invasive pneumococcal disease (IPD) by 
the vaccine serotypes among the vaccinees and substantial declines 
in IPD among unvaccinated populations such as older children and 
adults as well. In addition, there are increasing evidences to suggest 
that routine immunization with PCV7 is changing the epidemiology 
of pneumococcal diseases such as serotype distribution of IPD, 
nasopharyngeal colonization, and antibiotic resistance patterns. 
In contrast, there is an increase in the number of IPDs caused 
by nonvaccine serotypes, though it is much smaller than overall 
declines of vaccine serotype diseases. Several vaccines containing 
additional serotypes have been developed and tested clinically in 
order to expand the range of serotypes of Streptococcus pneumoniae. 
Recently two new pneumococcal protein conjugate vaccines, 
10-valent pneumococcal conjugate vaccine (PCV10) and 13-valent 
pneumococcal conjugate vaccine (PCV13), have been approved for 
use in several countries including Korea. This report summarizes the 
recommendations approved by the Committee on Infectious Diseases, 
the Korean Pediatric Society. 
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vaccines containing additional serotypes have been developed 
and investigated clinically to expand the range of serotypes of 
Streptococcus pneumoniae. Recently, two new pneumococcal 
protein conjugate vaccines 10-valent pneumococcal HiD-DiT 
In order to prevent pneumococcal diseases in infants and toddlers, 
the 7-valent pneumococcal CRM197 protein conjugate vaccine 
(PCV7, Prevenar, Wyeth/Pfizer) has been used as an optional 
vaccination in Korea since November 2003
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protein conjugate vaccine (PCV10, Synflorix, GSK, Inc., Belgium) 
and 13-valent pneumococcal CRM197 protein conjugate vaccine 
(PCV13, Prevenar13, Pfizer, Inc. USA) were approved in foreign 
countries. PCV10 was approved first in Canada in December 2008 
and then approved by the European Medicines Agency in March 
2009. PCV13 was approved first in Chile in July 2009 and then 
approved in the USA in February 2010.
In Korea, two vaccines PCV10 and PCV13 were almost 
simultaneously approved by the Korean FDA in March 2010. 
This report summarizes guidelines for the use of these two newly 
introduced pneumococcal protein conjugate vaccines as suggested 
by the Committee on Infectious Diseases of the Korean Pediatric 
Society (Box 1).
Pathogen
Streptococcus pneumoniae remains a leading cause of invasive 
infections including bacteremia and meningitis, as well as mucosal 
infections such as otitis media and pneumonia among children and 
adults. 
Streptococcus pneumoniae is a gram-positive diplococci and 
is classified into around 90 serotypes according to the serological 
property of their capsular polysaccharide. In some of the serotypes,   
the polysaccharide has similar physicochemical properties and 
antigenicity. Most pneumococcal infections are caused by ap-
proximately 10 serotypes, and common serotypes differ according to 
the region, period, and age group
2).
In Korea, Streptococcus pneumoniae is also believed to be the most 
common pathogen of bacterial diseases in children. A study analyzed 
the importance of Streptococcus pneumoniae in invasive infections 
and clinical manifestations of pneumococcal diseases in Korean 
children who were hospitalized for invasive infections caused by one 
of 8 major bacterial pathogens at 18 university hospitals across the 
country during a 10 year period from 1996 to 2005
3). According to 
the results from this study, pneumococcal infections were responsible 
for 44% (123 cases) of the 279 cases of invasive bacterial diseases in 
immunocompetent children aged between 3 months to 5 years
3). 
Serotypes 19F, 23F, 19A, 6B, 6A, 14, and 9V are common among 
the strains that were isolated from the nasopharynx and clinical 
specimens obtained from the children in Korea
4,5). In addition, 
according to the results of analyzing the pattern of change in the 
serotype distribution during the period from 1991 to 2006 at a single 
center, while PCV7-serotypes decreased before the introduction 
of PCV7, PCV7-related serotypes such as 6A and 19A were on an 
increasing trend
6). The decrease in the proportion of PCV7-serotype 
was even more prominent in invasive strains isolated from children 
aged under 2 years and those under 5 years. According to the data 
reported recently by the Korean Centers for Disease Control and 
Prevention
7), among 74 invasive strains isolated from infants aged 
under 5 years during the period from 1996 to 2008, serotypes 
included in PCV7 were 59.5% (n=34), 3 serotypes added to both 
PCV10 and PCV13 such as serotype 1 (n=2), 5 (n=0) and 7F (n=0) 
were 2.7% (n=2), and serotypes added to PCV13 only such as 3 (n=1), 
6A (n=8) and 19A (n=9) were 24.3% (n=18).
Vaccine components
PCV10 contains 10 serotype polysaccharides (1, 4, 5, 6B, 7F, 9V, 
14, 18C, 19F, and 23F) conjugated to 3 binding proteins; nontypeable 
Haemophilus influenzae protein D (NTHi protein D), diphtheria 
toxoid, and tetanus toxoid. PCV10 contains 1 μg of polysaccharide 
from each serotype 1, 4, 5, 6B, 7F, 9V, 14 and 23F, and 3 μg from 
each serotype 4, 18C and 19F. 9-16 μg of NTHi protein D, 5-10 μg 
of tetanus toxoid, and 3-6 μg of diphtheria toxoid are also included in 
the vaccine. The vaccine contains aluminum as aluminum phosphate 
adjuvant, and no thimerosal preservative. It is produced in the form of 
a 0.5 mL pre-filled syringe (Table 1).
PCV13 contains polysaccharides of 13 serotypes and diphtheria 
CRM197 protein. Six serotypes (1, 3, 5, 6A, 7F and 19A) are added 
Box 1. Summary of Recommendation for Use of Newly Introduced 
Pneumococcal Protein Conjugate Vaccines
1. Subjects and time of administration
Decide whether to administer after explaining to the guardian the risk of the 
disease, the benefits and cost of the vaccination, etc. Once the decision 
has been made, administer the vaccine as follows. 
1) 10-valent pneumococcal protein conjugate vaccine
For infants aged 6 weeks to 24 months, it is recommended that 3 doses 
are given at ages 2, 4, and 6 months, and a booster dose is given at 
age 12-15 months.
2) 13-valent pneumococcal protein conjugate vaccine
For infants aged 6 weeks to 59 months, it is recommended that 3 doses 
are given at ages 2, 4, and 6 months, and a booster dose is given at 
age 12-15 months.
Children aged 7 months and above who have not been vaccinated 
previously should receive 1-3 doses depending on their age at the time 
when vaccination began. Refer to the main contents of this document for 
more details. 
2. Administration and dose
Administer intramuscularly as a 0.5 mL dose
3. Adverse Reactions
There may be local responses such as pain, edema, erythema; systemic 
responses such as fever, irritable mood and poor appetite; and rare 
responses including convulsion, rash, itching, etc.
4. Contraindications
Follow the general contraindication guidelines for vaccination.148      EH Choi, et al. • Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea
to the 7 serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) in PCV7, and 
all 13 serotype polysaccharides individually conjugated to CRM197. 
PCV13 contains approximately 2 μg of polysaccharide from each of 
12 serotypes and 4 μg of polysaccharide from serotype 6B; the total 
concentration of CRM197 is 34 μg. The vaccine contains 0.125 mg 
of aluminum as aluminum phostphate adjuvant, and no thimerosal 
preservative. It is produced in the form of a 0.5 mL pre-filled syringe 
(Table 1).
Immunogenicity
Newly developed pneumococcal conjugate vaccines may be 
approved without clinical trials on efficacy by comparing its im-
munogenicity with pre-existing licensed vaccines. The criteria for 
evaluating the immunogenicity of newly developed pneumococcal 
protein conjugate vaccines suggested by the WHO are as follows
8). 
The evaluation of immunogenicity after primary vaccinations 
during infancy uses IgG antibody titer specific to each serotype, 
and the criteria for non-inferiority are the percentage of subjects 
whose antibody titer for each serotype measured through WHO 
reference ELISA is ≥0.35 μg/mL and the geometric mean titer 
of serotype-specific IgG. However, if the association of antibody 
titer is proved sufficiently through bridge study between another 
antibody test method and WHO reference ELISA, the method may 
be used instead. For example, anti-capsular antibody titer 0.2 μg/
mL measured by the antibody test method developed by GSK is 
equivalent to 0.35 μg/mL measured by WHO reference ELISA. As 
a secondary criterion, immunogenicity is evaluated by measuring 
functional antibody response through opsonophagocytosis assay 




Although the geometric mean concentration of anti-capsular IgG 
antibody was lower than that of PCV7, the WHO non-inferiority 
criteria was satisfied for 8 out of the 10 serotypes of PCV10 (5 out of 
the 7 PCV7-serotypes and 3 out of the newly added serotypes), but 
not for serotypes 6B and 23F. However, the OPA titer for these 2 
serotypes was high, and the percentages of subjects with an OPA titer 
≥1:8 was similar between PCV7 and PCV10 recipients. After the 4th 
booster dose, anti-capsular IgG antibody titers increased by 6-7 fold 
and OPA titers by 8-93 fold compared to those before vaccination
5).
2. PCV13 
Among infants receiving the 3-dose primary infant series, 3 
serotypes (6B, 9V, and 3) did not meet the primary endpoint criteria 
1 month after the third dose, but all serotypes had detectable OPA 
antibodies and the percentages of subjects with an OPA antibody titer 
≥1:8 were similar between PCV13 recipients (range: 90%‒100%) 
and PCV7 recipients (range: 93%‒100%). After the fourth dose, 
the non-inferiority criteria for anti-capsular IgG Ab geometric mean 
concentrations was met for 12 of the 13 serotypes; the non-inferiority 
criteria was not met for the response to serotype 3. Detectable OPA 
antibodies were present for all serotypes of the fourth dose; the 
percentage of PCV13 recipients with an OPA titer ≥1:8 ranged from 
97%‒100% for the 13 serotypes and was 98% for serotype 3
10).
The efficacy and effectiveness of the vaccines 
No efficacy data is available for the two newly developed vaccines 
against invasive pneumococcal diseases, pneumonia, otitis media, 
and nasopharyngeal carriage. At the moment, the efficacy of PCV13 
against pneumococcal diseases is predicted to be similar to the 
established efficacy and effectiveness of PCV7 in preventing invasive 
pneumococcal diseases, pneumonia, otitis media and reduction in 
Table 1. The Components of the New Pneumococcal Protein Conjugate Vaccines and the Contents of Approval by the Korean FDA
10-valent pneumococcal HiD-DiT protein conjugate vaccine 
(PCV10-HiD-DiT)
13-valent pneumococcal CRM197 protein conjugate 
vaccine (PCV13-CRM197)
Product name (manufacturer) Synflorix (GSK) Prevenar13 (Pfizer)
Components Protein D conjugate serotypes: 1, 4, 5, 6B, 7F, 9V, 14, 23F
tetanus toxoid conjugate serotype: 18C
diphtheria conjugate serotype: 19F
4, 6B, 9V, 14, 18C, 19F, 23F
1, 3, 5, 6A, 7F, 19A
Diphtheria CRM197 conjugate protein
Contents of approval by
the Korean FDA
Prevention of invasive diseases by 10 serotypes 
(1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) in infants aged 
between 6 weeks–<2 years
Prevention of invasive diseases by 13 serotypes above 
(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in 
infants aged between 6 weeks–5 years
Prevention of acute otitis media by the 10 serotypes above in 
infants aged between 6 weeks–<2 years (however, data on the 
effectiveness of 1, 5 and 7F against acute otitis media are not 
sufficient)
Prevention of acute otitis media by the 13 serotypes above 
in infants aged between 6 weeks–5 years (however, data 
on the effectiveness of 1, 3, 5, 6A, 7F and 19A against 
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nasopharyngeal carriers, and its preventive effectiveness is yet to be 
observed in the future.
Likewise, no research data has been reported on the efficacy and 
preventive effectiveness of PCV10. However, research has been done 
on the efficacy of 11-valent pneumococcal HiD protein conjugate 
vaccine (PCV11) against otitis media and nasopharyngeal carriers
11). 
PCV11 is different from PCV10 in that it contains an additional 
serotype 3, and contains only one type of protein, NTHi protein D, 
that each serotype polysaccharide is conjugated to.  
Safety
PCV10 and PCV13 are safe vaccines, comparable to safety of 
PCV7. Common adverse reactions include local responses such as 
pain, edema, and erythema in the injection site; systemic responses 
such as fever, irritability, and poor appetite; and rare adverse reactions 
such as convulsion, rash or itching.
Indications for Use (Table 1)
1. PCV10
1) Prevention of invasive diseases by 10 serotypes (1, 4, 5, 6B, 7F, 
9V, 14, 18C, 19F, 23F) in infants aged between 6 weeks–<2 years
2) Prevention of acute otitis media by the 10 serotypes above 
in infants aged between 6 weeks–<2 years (however, data on 
the effectiveness of 1, 5 and 7F against acute otitis media are not 
sufficient)
2. PCV13
1) Prevention of invasive diseases by 13 serotypes (1, 3, 4, 5, 6A, 6B, 
7F, 9V, 14, 18C, 19A, 19F, 23F) in infants aged between 6 weeks–5 
years (71 months)
2) Prevention of acute otitis media by the 13 serotypes above in 
infants aged between 6 weeks–5 years (71 months) (however, data on 
the effectiveness of 1, 3, 5, 6A, 7F and 19A against acute otitis media 
are not available).
Subjects and method of administration
1. Administration method
Both vaccines are administered intramuscularly as a 0.5 mL dose.
2. Subjects
1) PCV10 (Table 2)
(1) Infants aged between 6 weeks-6 months
ⅰ) Primary series: Administer 3 doses at ages 2, 4, and 6 months.
ⅱ) Booster dose: The fourth dose is recommended at age 12-15 
months and at least 6 months after the third dose. 
(2) Infants aged 7 months or older who have not been completely 
vaccinated 
ⅰ) Infants aged 7‒11 months: Administer two doses with a 
minimum interval of one month. The 3
rd dose is recom-
mended at age ≥12 months with a minimum interval of 2 
months from the 2
nd dose. 
ⅱ) Infants aged 12‒23 months: Administer two doses with a 
minimal interval of 2 months. It has not yet been established 
whether a supplemental dose is necessary after the 2
nd dose.
2) PCV13
It is recommended to administer in infants aged between 2‒59 
months. In addition, vaccination is also recommended for all children 
aged 60‒71months with underlying medical conditions that increase 
their risk for pneumococcal disease or complications (Table 3)
12,13).
Table 2. Recommendation for Use of 10-valent Pneumococcal HiD-
DiT Protein Conjugate Vaccine (PCV10) according to the Age at Time of 
First Vaccination
Age at first dose Primary PCV10 series* PCV10 booster vaccination
†
2-6 months 3 times Once in 12-15 months after birth
7-11 months 2 times Once in 12-15 months after birth
12-23 months 2 times -
*The minimum interval between doses is 1 month for infants aged less 
than 1 year, and 2 months for those aged 1 year or older. Minimum age for 
administration is 6 weeks
†Administered at least 2 months after the previous dose 
Table 3. Classification of Risk Groups according to Underlying Disease 
Indicating the Administration of Pneumococcal Vaccine
Risk group  Disease






Children with functional or  Sickle cell anemia or hemoglobinopathies




Chronic renal failure and nephrotic syndrome
Disease associated with treatment with immu-
nosuppressive agents or radiation (malignant 
tumor, leukemia, lymphoma, Hodgkin disease 
or solid organ transplantation)
Congenital immunodeficiency
‡
This table was adapted from the reference 13).
*In particular, congenital cyanotic heart disease and heart failure
†Include asthma patients taking high-dose oral steroid 
‡B-cell (humoral immunity) or T-cell deficiency, complement deficiency (in 
particular, C1, C2, C3 and C4 deficiency), macrophage disease (excluding 
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(1) No previous PCV7/PCV13 vaccination (Table 4)
For infants and toddlers aged 2‒59 months, recommendations are 
the same as those previously published for PCV7.
1) 
A. Infants aged 2‒6 months
ⅰ) Primary series: Administer 3 doses at ages 2, 4, and 6 months 
at intervals of approximately 8 weeks. The first dose can be 
administered as early as 6 weeks, and the minimum interval 
is 4 weeks. 
ⅱ) Booster dose: The fourth dose is recommended at age 12‒15 
months and at least 8 weeks after the third dose. 
B. Children aged ≥7 months
ⅰ ) Infants aged 7‒11 months: The first 2 doses should be 
administered with an interval of at least 4 weeks between 
doses. The third dose should be administered at age ≥12 
months, at least 8 weeks after the second dose. 
ⅱ) Infants aged 12‒23 months: Two doses are recommended, 
with an interval of at least 8 weeks between doses.
ⅲ) Infants aged >24 months: Unvaccinated healthy children 
aged 24‒59 months should receive a single supplemental 
dose. Unvaccinated children aged 24‒71 months with 
underlying medical conditions increasing the risk for 
pneumococcal disease (Table 3) should receive 2 doses with 
an interval of at least 8 weeks between doses.
(2) Incomplete PCV7/PCV13 Vaccination (Table 5) 
Infants and children who have received ≥ 1 dose of PCV7 should 
complete the vaccination series with PCV13. 
A. Children aged <24 months 
ⅰ) Children aged 12‒23 months who have received 3 doses of 
PCV7 before age 12 months are recommended to receive 1 
dose of PCV13, administered at least 8 weeks after the most 
recent dose of PCV7
ⅱ) No additional PCV13 doses are recommended for children 
aged 12‒23 months who received 2‒3 doses of PCV7 before 
age 12 months and at least 1 dose of PCV13 at age ≥12 
months.
B. Children aged ≥24 months
ⅰ) One dose of PCV13 is recommended for all healthy children 
aged 24‒59 months with any incomplete PCV schedule. 
ⅱ) For children aged 24‒71 months with underlying medical 
conditions who have received any incomplete schedule of 
<3 doses of PCV, 2 doses of PCV13 are recommended with 
intervals of at least 8 weeks. For those who have received 3 
doses of PCV, a single dose of PCV13 is recommended.
(3) Complete PCV7 vaccination
ⅰ) A single supplemental dose of PCV13 is recommended for 
all children aged 14‒59 months who have received 4 doses of 
PCV7 or another age-appropriate, complete PCV7 schedule. 
ⅱ) For children who have underlying medical conditions, a 
single supplemental PCV13 dose is recommended through 
71 months. This includes children who have received 
23-valent pneumococcal polysaccharide vaccine (PPSV23) 
previously. 
ⅲ) A supplemental dose should be administered at least 8 weeks 
after the most recent dose of PCV or PPSV23.
(4) Children aged 6‒18 years in high-risk conditions
A single dose of PCV13 may be administered for children who 
have not received PCV13 previously and are at increased risk for 
invasive pneumococcal disease because of anatomic or functional 
asplenia, including sickle cell disease, immunocompromising 
conditions such as HIV infection, cochlear implant, or cerebrospinal 
Table 4. Recommended Schedule for Use of 13-valent Pneumococcal 
Protein Conjugate Vaccine (PCV13) PCV13 in Infants Who Have Never 
Received Pneumococcal Vaccines







2-6  3 doses 1 dose at 12-15 months
7-11  2 doses 1 dose at 12-15 months
12-23  2 doses -
24-59 in healthy children 1 dose -
24-71 in children with 




*The minimum interval is 4 weeks for infants <12 months, and 8 weeks for 
children ≥12 months. Minimum age for first dose is 6 weeks
†Administer at least 8 weeks after the previous dose
‡Described in Table 3
Table 5. 7-valent Pneumococcal Protein Conjugate Vaccine (PCV7) 
and 13-valent Pneumococcal Protein Conjugate Vaccine (PCV13) 
Immunization Schedule according to the Number of Previous PCV7 
Doses Received
Infant series Booster dose Supplemental dose
2 months 4 months 6 months Over 12 months* 14-59 months
†
PCV7 PCV13 PCV13 PCV13 -
PCV7 PCV7 PCV13 PCV13 -
PCV7 PCV7 PCV7 PCV13 -
PCV7 PCV7 PCV7 PCV7 PCV13
*No additional PCV13 doses are indicated for children aged 12-23 months 
who have received 2 or 3 doses of PCV7 before age 12 months and at least 
1 dose of PCV13 at age ≥12 months.
†For children with underlying medical conditions as in table 3, a supplemental 
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fluid leaks, regardless of whether they have previously received PCV7 
or PPSV23.
Interchangeability 
As mentioned in the immunization schedule (Table 5), it is possible 
to switch vaccines from previously administered PCV7 to PCV13. 
With regard to interchangeability between PCV7 and PCV10, 
there is a study that compared immunogenicity between two cases 
where the first had completed 3 doses of primary infant series with 
PCV7 following a 4th booster dose with PCV10, and another had 
completed both the primary infant series and booster dose with 
PCV10
9). Results showed that antibody titers for the 7 serotypes 
included in PCV7 increased sufficiently in both groups. However, 
there has not been any study comparing the immunogenicity of 
cross-administration between PCV7 and PCV10 for the primary 
infant series. So, at the moment, PCV10 after completion of primary 
infant series with PCV7 can be administered. However, it is not 
recommended to cross-administer PCV10 and PCV13 during 
primary infant series. 
Contraindications
Follow the general contraindication guidelines for vaccination.
 References
  1)  The Korean Pediatric Society. Pneumococcal vaccine. In: Lee HJ, editor. 
Immunization Guideline. 6th ed. Seoul: The Korean Pediatric Society, 
2008;196-216.
 2)  Dagan R, Jacobs MR, Greenberg D. Pneumococcal infections. In: Feigin 
RD, Cherry JD, Demmler GJ, Kaplan S, editors. Textbook of Pediatric 
Infectious Diseases. 5th ed. Philadelphia: WB Saunders, 2004;1204-58.
 3)   Lee JH, Cho HK, Kim KH, Kim CH, Kim DS, Kim KN, et al.   
Etiology of invasive bacterial infections in immunocompetent children in 
Korea (1996-2005): A retrospective multicenter study. J Korean Med Sci 
2011;26:174-83. 
 4)  Kim SH, Song EK, Lee JH, Kim NH, Lee JA, Choi EH, et al. Changes of 
serotype distribution of Streptococcus pneumoniae isolated from children 
in Korea over a 15 year-period (1991-2005). Korean J Pediatr Infect Dis 
2006;13:89-98.
 5)  Lee TJ, Chun JK, Choi KM, Yong DE, Lee KW, Kim DS. Trends in 
serotype distribution of clinical isolates of Streptococcus pneumoniae: a 
single center experience from 2001 to 2006. Korean J Pediatr Infect Dis 
2006;13:115-23.
 6)  Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee HJ, et al. Strepto-
coccus pneumoniae serotype 19A in children, South Korea. Emerg Infect 
Dis 2008;14:275-81.
 7)  Korean Centers for Disease Control and Prevention. Serotype distribution 
and antimicrobial susceptibility of invasive Streptococcus pneumoniae 
clinical isolates in Korea. Public Health Wkly Rep 2010;3:1-7.
 8)  World Health Organization. Technical Report Series, No. 927, Annex 
2. Recommendations to assure the quality, safety and efficacy of pneu-
mococcal conjugate vaccines, 2009. 
 9)  Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, 
et al. Immunogenicity of the 10-Valent pneumococcal non-typeable 
Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) 
vompared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28(4 
Suppl):S66-S76.
10)  Food and Drug Administration. Prevnar 13: clinical review of new product 
license application. Rockville, MD: Food and Drug Administration, 2010.
11)   Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et 
al. Pneumococcal capsular polysaccharides conjugated to protein D for 
prevention of acute otitis media caused by both Streptococcus pneumoniae 
and nontypeable Haemophilus influenzae: a randomised double-blind 
efficacy study. Lancet 2006;367:740-8.
12)  Centers for Disease Control and Prevention. Licensure of a 13-valent 
pneumococcal conjugate vaccine (PCV13) and recommendations for 
use among children-Advisory Committee on Immunization Practices 
(ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010;59:258-61. 
13)  Nuorti JP, Whitney CG;Centers for Disease Control and Prevention. 
Prevention of pneumococcal disease among infants and children – Use of 
13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal 
polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 2010;59(RR-
11):1-18.